Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.

What Was Tested

This randomized controlled trial looks at Glucagon.

After weight-loss surgery, some patients experience postbariatric hypoglycemia (PBH).

Although PBH is customarily managed by dietary modifications with continuous glucose monitoring, advanced treatment options are needed.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

This 3-part, phase 1, double-blind study enrolled healthy adults.

The primary end point was safety/tolerability (treatment-emergent adverse events [TEAEs]).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

PK (SAD/MAD; time-to-maximal concentration [tmax] and half-life [t1/2]) and PD (MAD; GLP-1 and glycemic parameters during a mixed meal tolerance test [MMTT]) were assessed.

Imapextide drug-drug interactions (DDIs) of OATP1B1/OATP1B3 inhibition and accelerated gastric emptying were evaluated with coproporphyrin-I, rosuvastatin, and acetaminophen.

What Was Measured

The subject headings attached to it are Healthy Volunteers, Glucagon-Like Peptide-1 Receptor, Blood Glucose and Hypoglycemia.

The authors tagged it with the keywords GLP-1 receptor antagonist, bariatric surgery, clinical trial, imapextide, phase 1 and postbariatric hypoglycemia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page, all human trials.